The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database.

TitleThe prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database.
Publication TypeJournal Article
Year of Publication2017
AuthorsBa M, Li X, Ng KPin, Pascoal TA, Mathotaarachchi S, Rosa-Neto P, Gauthier S
Corporate AuthorsAlzheimer's Disease Neuroimaging Initiative
JournalAlzheimers Dement (N Y)
Volume3
Issue1
Pagination107-113
Date Published2017 Jan
ISSN2352-8737
Abstract

INTRODUCTION: The prevalence and detailed biomarkers' characteristic of rapidly progressive Alzheimer's disease (rpAD) remain incompletely understood.METHODS: A total of 312 mild AD patients from the Alzheimer's Disease Neuroimaging Initiative database were chosen and dichotomized into rpAD and non-rpAD groups. We performed the prevalence and comprehensive biomarker evaluation.RESULTS: The prevalence of rpAD was 17.6% in mild AD. Compared with non-rpAD, there were no differences in APOE ε4/ε4, APOE ε3/ε4, and APOE ε2/ε4 genotype distribution, cerebrospinal fluid tau, phosphorylated tau (p-tau), amyloid-β, hippocampus volume, and amyloid deposition in rpAD. Yet, a lower p-tau/tau ratio was observed in rpAD (P = .04). rpAD showed region-specific hypometabolism ([18F]fluorodeoxyglucose-positron emission tomography [FDG-PET]) (P = .001). Receiver-operating characteristic analysis of FDG-PET demonstrated that left angular and left temporal cortices were the regions with higher area under the curve and predictive value for identifying clinical at-risk rpAD.DISCUSSION: We identified that rpAD commonly existed in mild AD. Cerebral hypometabolism could provide potential clinical differential value for rpAD in the short-term follow-up period.

DOI10.1016/j.trci.2016.12.005
Alternate JournalAlzheimers Dement (N Y)
PubMed ID29067322
PubMed Central IDPMC5651370